Home » Newsletters » BioWorld Science

BioWorld Science

June 13, 2018

View Archived Issues

Tac2 neuropeptide system regulates behavioral changes caused by chronic social isolation in mice

Pluristem presents topline results from phase II study of PLX-PAD cells

Results from first-in-human GAPVAC-101 trial of APVAC vaccines in newly diagnosed glioblastoma

Second-generation HIF-2-alpha inhibitor PT-2977 well tolerated in first-in-human trial

ITGB3 gene polymorphism is positively associated with pericellular fibrosis in patients with NAFLD

Novel gene therapy for the treatment of Rett syndrome demonstrates efficacy and safety in vivo

IL18-secreting CAR T cells have improved antitumor activity and promote endogenous immune responses

FDA grants rare pediatric disease designation to A-4250

BridgeBio to acquire ALXN-1101 from Alexion for MoCD type A

Alexion and Complement partner to codevelop CP-010 for neurodegenerative disorders

Cynata reports 6-month data from cohort A of phase I trial of CYP-001 in acute GvHD

Ganovo approved in China for hepatitis C

CStone initiates pivotal studies of CS-1001 in China

Bioelectron Technology presents new imidazole compounds

4D Pharma gains further clearances to conduct phase II study of Blautix for IBS

Bristol-Myers Squibb patents TYK2 inhibitors

IMPACT Therapeutics identifies WEE1hu inhibitors

FDA approves Keytruda for recurrent or metastatic cervical cancer whose tumors express PD-L1

E-Scape Bio obtains rights to S1P5 receptor agonists from AbbVie for lysosomal storage disorders

Galmed reports 1-year data from phase IIb study of Aramchol in NASH

Herantis initiates phase II study of Lymfactin for secondary lymphedema

Senhwa Biosciences and PBTC to study CX-4945 in pediatric recurrent medulloblastoma

ProQR Therapeutics enters partnership to advance development of QR-313

Japanese authorities grant priority review to lorlatinib application

FDA awards fast track designation to RGX-111 for MPS I

Recommended phase II dose established in first-in-human study of 2X-121

Tyme reports detailed data from first-in-human study and compassionate use program of SM-88

Phase II study of IMO-8400 in dermatomyositis does not meet primary endpoint

Sage announces expedited SAGE-217 development plan